A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
about
Mutant alpha-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinomaInteraction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-cateninA gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytesIdentification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytesNormal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytesHuman tumor antigens recognized by T lymphocytesTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesSafety of targeting tumor endothelial cell antigensT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Tumor neoantigens: building a framework for personalized cancer immunotherapyExpression of tumor-rejection antigens in gynecologic cancersbeta-catenin signaling and cancerCytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptideSerine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patientsCleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patientsTumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genesPRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cellsPre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapyExpression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patientsTumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid ClassesPhotodynamic therapy of tumors can lead to development of systemic antigen-specific immune responseBiochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsAutoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancerSequence analysis of genes encoding rodent homologues of the human tumor-rejection antigen SART-1.T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.Advances in cancer vaccine development.Human tumor antigens for cancer vaccine development.High sensitivity of cancer exome-based CD8 T cell neo-antigen identificationImmunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomasImmunologic approaches to antigen discovery for cancer vaccines.Heat shock proteins: the fountainhead of innate and adaptive immune responses.Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.Innovations and strategies for the development of anticancer vaccines.Gene therapy: development of immunostimulatory treatments for cancer.
P2860
Q24321856-2C2C9017-78B8-4D27-B491-FF2B23E73BAEQ24522854-64675B8E-196E-43E1-9400-FA9568B65343Q24647420-87B71622-3AF4-4AC9-A217-F261D0F26835Q24647904-1DCF93E1-BB11-449E-B523-9ED7C8525CC2Q24648492-28B41E8F-B211-4939-812F-D6A5238E58FEQ24649346-14314E24-9514-4EEC-BDA2-A923BEBD8388Q24678508-F0118811-90AF-4F0D-B3B2-80A3C56517ADQ24804837-7517FCE6-1DEA-4BF7-BF24-C8466AD21E5FQ26748863-D1166A07-57D3-4DCD-9C56-C8579752E13CQ27335110-89A5C241-3482-4C44-B4EF-7256291FCF46Q28082704-09C24E3A-330D-4289-A50B-BC3D50DC088FQ28138549-3B93358E-B5EB-42C8-B7ED-419F32DF7893Q28139147-26D82438-BCB1-4B0E-B04D-DE8EF9DECC81Q28146219-961D27DD-E3A3-4959-BD49-30591A6DCCE5Q28202640-85056EDA-D741-4339-86E3-919B346285A9Q28216625-ED401BC3-81CA-43F6-9C1B-A32DED49860BQ28219945-7F797A5E-2935-4752-9269-820A445ABCC8Q28283719-90D6424E-4F49-408C-A9B9-DA770B6071D0Q28344557-055A4D76-8838-4F39-A8D2-BDA91B2AA4AEQ28361963-F3E40FE9-3964-40B0-AD29-8757E8A88DEEQ28554412-7BEC17AD-C641-4343-8217-15F57DC21F97Q28744245-1679DA0D-88CC-41D9-94CA-3FA8982B21C3Q30442808-857624AC-276B-4512-A9D4-C2641FDDAF25Q30442838-49EFB1E2-D4FE-4A43-8CDC-0886A3C0B819Q30442906-5F8417A9-C045-4D6B-8797-6916944C1E19Q30621114-FC239CF0-6ED0-40B7-9BFA-7B43C94FA9E9Q31042618-C783ED7F-9D2A-410D-A013-A0CDDAAB24C2Q32002952-D5753AB9-787D-4F92-9748-932ABE4F78BEQ33202641-D0AEDAE8-6E87-4CB3-854A-4722BCEE00C3Q33210267-A1735425-51A4-425E-9A33-1B4DB13E4A7EQ33603404-756C799E-3E23-4DA5-B79E-E2EE4C39CBD3Q33776127-AF941C2E-3676-4FF9-89A1-BB5D10A79D20Q33930588-2450E620-5340-4C37-AB72-1DD5C59C2041Q34060255-484AE01E-4C3E-4588-84A1-97ABAE8849D0Q34067016-F0F001BD-14E1-4405-8B5A-6F828DF93100Q34074742-BD006D37-C397-4155-89B6-F7FD6D6A192CQ34145113-253161C5-12DF-452F-A0D3-A2B05E64A3A6Q34173622-D5076E63-23DF-4D63-B88F-43C1B9B7184BQ34182039-54BA5A4E-FE03-454E-A91E-B9C598743A02Q34187915-27BE4900-0F25-431E-A2FB-CB326EDFFB72
P2860
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
A mutated beta-catenin gene en ...... umor infiltrating lymphocytes.
@ast
A mutated beta-catenin gene en ...... umor infiltrating lymphocytes.
@en
type
label
A mutated beta-catenin gene en ...... umor infiltrating lymphocytes.
@ast
A mutated beta-catenin gene en ...... umor infiltrating lymphocytes.
@en
prefLabel
A mutated beta-catenin gene en ...... umor infiltrating lymphocytes.
@ast
A mutated beta-catenin gene en ...... umor infiltrating lymphocytes.
@en
P2093
P2860
P356
P1476
A mutated beta-catenin gene en ...... umor infiltrating lymphocytes.
@en
P2093
El-Gamil M
Kawakami Y
Robbins PF
Rosenberg SA
P2860
P304
P356
10.1084/JEM.183.3.1185
P407
P577
1996-03-01T00:00:00Z